Theralink Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
May 15, 2023 at 04:13 pm EDT
Share
Theralink Technologies, Inc. reported earnings results for the second quarter and six months ended March 31, 2023. For the second quarter, the company reported sales was USD 0.169787 million compared to USD 0.0195 million a year ago. Net loss was USD 8.57 million compared to USD 1.84 million a year ago.
For the six months, sales was USD 0.225082 million compared to USD 0.098475 million a year ago. Net loss was USD 45.02 million compared to USD 3.35 million a year ago. Basic loss per share from continuing operations was USD 0.01.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.